中国民康医学
中國民康醫學
중국민강의학
MEDICAL JOURNAL OF CHINSEE PEOPLE HEALTH
2015年
4期
16-17,86
,共3页
佐匹克隆%老年%失眠症
佐匹剋隆%老年%失眠癥
좌필극륭%노년%실면증
Zopiclone%Elderly%Insomnia
目的::探讨采用佐匹克隆治疗老年失眠症的临床效果及安全性。方法:选取90例老年失眠症患者,随机将其分成研究组和对照组各45例。对照组患者每晚睡前服用1mg艾司唑仑,而研究组患者则在每晚睡前服用7.5 mg佐匹克隆,共服用2周,利用睡眠障碍量表(SDRS)和药物不良反应量表(TESS)对两组患者的治疗效果及不良反应进行分析比较。结果:研究组患者治疗总有效率为95.6%,显著高于对照组77.8%的治疗总有效率,差异具有统计学意义(P<0.05);研究组患者治疗后SDRS评分较治疗前和对照组治疗后均明显缩短,数据差异具有统计学意义(P<0.05);研究组患者不良反应发生率明显低于对照组(P<0.01)。结论:在老年失眠症患者中采用佐匹克隆治疗方案具有更显著的疗效,安全性更高,不良反应少,值得临床推广及应用。
目的::探討採用佐匹剋隆治療老年失眠癥的臨床效果及安全性。方法:選取90例老年失眠癥患者,隨機將其分成研究組和對照組各45例。對照組患者每晚睡前服用1mg艾司唑崙,而研究組患者則在每晚睡前服用7.5 mg佐匹剋隆,共服用2週,利用睡眠障礙量錶(SDRS)和藥物不良反應量錶(TESS)對兩組患者的治療效果及不良反應進行分析比較。結果:研究組患者治療總有效率為95.6%,顯著高于對照組77.8%的治療總有效率,差異具有統計學意義(P<0.05);研究組患者治療後SDRS評分較治療前和對照組治療後均明顯縮短,數據差異具有統計學意義(P<0.05);研究組患者不良反應髮生率明顯低于對照組(P<0.01)。結論:在老年失眠癥患者中採用佐匹剋隆治療方案具有更顯著的療效,安全性更高,不良反應少,值得臨床推廣及應用。
목적::탐토채용좌필극륭치료노년실면증적림상효과급안전성。방법:선취90례노년실면증환자,수궤장기분성연구조화대조조각45례。대조조환자매만수전복용1mg애사서륜,이연구조환자칙재매만수전복용7.5 mg좌필극륭,공복용2주,이용수면장애량표(SDRS)화약물불량반응량표(TESS)대량조환자적치료효과급불량반응진행분석비교。결과:연구조환자치료총유효솔위95.6%,현저고우대조조77.8%적치료총유효솔,차이구유통계학의의(P<0.05);연구조환자치료후SDRS평분교치료전화대조조치료후균명현축단,수거차이구유통계학의의(P<0.05);연구조환자불량반응발생솔명현저우대조조(P<0.01)。결론:재노년실면증환자중채용좌필극륭치료방안구유경현저적료효,안전성경고,불량반응소,치득림상추엄급응용。
Objective:To investigate clinical efficacy and safety of Zopiclone in treatment of insomnia in the elderly. Meth-ods:90 cases of elderly patients with insomnia were randomly divided into study group and control group, 45 cases in each group. The patients of control group took 1mg Estazolam every night at bedtime for two weeks, while those in study group took 7. 5mg Zopiclone ev-ery night at bedtime for two weeks. The treatment effects and adverse reactions in both groups were analyzed and compared by using sleep dysfunction rating scale ( SDRS) and treatment emergent symptom scale ( TESS) . Results:The total effective rate of study group was 95. 6%, and was significantly higher than 77. 8% of control group, and the difference was statistically significant (P<0. 05). The SDRS scores of study group after the treatment were significantly lower than those before the treatment and control group after the treat-ment, and the differences were statistically significant (P<0. 05). The incidence rates of adverse reactions of study group were signifi-cantly lower than those of control group (P<0. 01). Conclusions:In elderly insomnia, Zopiclone has a more significant effect, more safety, and less adverse reactions, and is worthy of promotion and application.